Clovis Oncology | GenomeWeb

Clovis Oncology

FDA clearance of the first NGS companion diagnostic paves the way for other comprehensive genomic profiling tests, but Foundation will have to educate docs on the benefits of its test.

The test is approved to identify patients who harbor BRCA mutations and are therefore more likely to respond to Clovis Oncology's ovarian cancer drug Rubraca.

Clovis hopes Sysmex's BEAMing test will work better than FFPE tests to identify candidates for treatment with rociletinib, its investigational EGFR inhibitor.

Interim data showed 40 percent of patients with a DNA repair signature experienced tumor shrinkage when treated with the drug.

Originally published August 8.
NEW YORK (GenomeWeb) – Clovis Oncology this week reported that the company had incurred a net loss for the second quarter of $34.8 million, compared to $19.3 million in the second quarter of 2013.

FDA Clears Sequenom's IMPACT Dx to Aid Thrombophilia Diagnosis
The US Food and Drug Administration this week cleared Sequenom's IMPACT Dx Factor V Leiden and Factor II genotyping test.

A team led by researchers at the University of Copenhagen has completed a proteome-wide analysis of protein-polyADP-ribosylation, or PARylation, a post-translational modification thought to play a key role in DNA damage repair.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.